Lanreotide Acetate

Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three Phase III readouts expected in H2 2026 Confirmation of full-year 2026 guidance 2 PARIS, FRANCE, 23 April 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2026. Q1 2026 % change €m Actual CER Oncology 707.5 8.0 % 13.0 % Rare Disease 147.1 109.1 % 125.4 % Neuroscience 220.3 13.8 % 18.5 % Total Sales 1,074.9 17.0% 22.6% “Ipsen has delivered a strong start to 2026,” said David Loew, Chief Executive Officer, Ipsen. “We advanced our strategic priorities across the business, combining strong top‑line performance with continued pipeline progress. I am very pleased with the growth of our rare liver disease franchise with the performance of Iqirvo and Bylvay. Additionally, with three Phase III readouts expected this year and three new late-stage programs starting, Ipsen is well-positioned to drive sustainable growth and deliver meaningful value for patients.” Full-year guidance 2026 Ipsen is confirming its financial guidance 3 for full-year 2026: Total sales growth greater than 13.0%, at constant currency, assuming accelerated sales growth of the portfolio excluding Somatuline and the growth of Somatuline sales due to generic lanreotide challenges. Based on the average level of exchange rates in March 2026, an adverse effect on total sales of around 1% of currencies is expected Core operating margin greater than 35.0% of total sales Upcoming 2026 milestones Ipsen anticipates several key milestones across its portfolio in 2026, including: Iqirvo ® (ELSPIRE trial) – Readout of pivotal Phase III in primary biliary cholangitis Bylvay ® (BOLD trial) – Readout of pivotal Phase III in biliary atresia Dysport ® (BEOND trials) – Readout of pivotal Phase III trials in chronic and episodic migraine Corabotase (IPN10200, LANTIC trial) – Readout of Phase II in lateral canthal lines and forehead lines Data from stage 1 of the Phase II LANTIC trial of corabotase (IPN10200) will be presented at the Music City SCALE (Symposium for Cosmetic Advances and Laser Education) 2026 symposium in May. Pipeline update On 30 January 2026, Ipsen expanded its pre‑clinical pipeline in rare neurodegenerative diseases through a global collaboration and exclusive option agreement with Origami Therapeutics. The partnership focuses on a research‑stage protein‑degrader program targeting genetic neurodegenerative diseases. Should Ipsen exercise its option following successful drug‑candidate nomination, the Company would assume full responsibility for global development and commercialization, reinforcing its strategy in rare neuroscience and first‑in‑class innovation. On 9 March 2026, Ipsen announced the voluntary withdrawal of Tazverik ® (tazemetostat) from all indications and all Ipsen markets, effective immediately, following emerging safety data from the ongoing Phase Ib/III SYMPHONY‑1 trial in follicular lymphoma. On 22 April 2026, following the positive European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion, Ipsen was granted conditional marketing authorization by the European Commission (EC) for Ojemda ® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement or BRAF V600 mutation, who have progressed after one or more prior systemic therapies. Approval is based on the pivotal Phase II FIREFLY-1 data demonstrating meaningful and durable tumor responses. Conference call A conference call and webcast for investors and analysts will begin today at 2pm CET. Participants can access the call and its details by registering here ; webcast details can be found here . Calendar Ipsen intends to publish its half-year results on 30 July 2026. Notes All financial figures are in € millions (€m). The performance shown in this announcement covers the three-month period to 31 March 2026 (Q1 2026, the quarter), compared to the three-month period to 31 March 2025 (Q1 2025) unless stated otherwise. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com . Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers . The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . 1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period. 2 Total sales growth greater than 13.0%, at constant currency and core operating margin greater than 35.0% of total sales. 3 Excludes any impact from potential late-stage (Phase III clinical development or later) business development transactions. Attachment Ipsen PR_Q1 2026_23042026

全球医疗行业每日重点资讯 文 | 苏丁 企业动态 西门子正式公布西门子医疗分拆时间表，计划在2027年2月的年度股东大会上分拆方案投票表决，西门子医疗“去母公司化”进程再迎重大进展。去年11月，西门子正式官宣，拟剥离其在西门子医疗剩余的股份（彼时约为67%），计划通过分拆的方式将西门子医疗30%的股份转让给西门子股份公司的股东，从而将西门子医疗从其合并报表中剥离。西门子认为，这种方法最能为两家公司的股东保留价值。 全球牙科巨头义获嘉（Ivoclar）集团与莘庄工业区正式签署项目合作协议，宣布一期投资1000万美元建设自动化牙科医疗器械生产线。这也是义获嘉在华建立的首个生产制造项目。该项目将聚焦牙科填充材料、粘接剂等核心产品的本土化生产，产品广泛覆盖牙齿直接修复、固定修复、活动修复及口腔预防、牙齿美容等全牙科领域。 亚马逊将通过其初级保健部门One Medical推出一个项目，提供GLP-1疗法。该公司表示，与其它供应商提供的一次性体重管理方案相比，这个新项目旨在提供持续的医疗监督，让临床医生能够监测进展、调整治疗方案并处理相关的健康问题。通过该项目，客户可以获得诺和诺德的Wegovy以及礼来公司的Foundayo GLP-1减肥药片，有保险覆盖的起价为每月25美元，自费选项则为每月149美元。 百时美施贵宝计划在新泽西州裁员206人，裁员将于7月中旬至2026年底之间生效。此次裁员标志着该公司持续两年的重组计划的最新进展，公司一直在稳步减少公司员工人数。 英矽智能宣布成立行业首个长寿委员会。委员会关注的领域包括：生命模型研究、衰老生物标志物开发、识别同时与衰老、长寿及疾病相关的双重用途靶点，以及通过生物标志物和基础模型验证治疗药物对衰老关键特征影响的临床开发。委员会主席由礼来公司分子发现集团副总裁Andrew Adams担任。 商汤医疗已于年初完成超5亿元战略融资，公司估值正式迈入10亿美元独角兽行列。此次A轮融资，由Raffles Healthcare Growth Fund、新加坡狮城资本、香港高才基金、华盖资本、国科资本、远东宏信资本、上海临港基金、架桥资本、宏沣资本等多家知名产业资本、国资平台及头部财务机构联合投资。联想创投等老股东也继续加码。商汤医疗正在推进全球医疗世界模型赛道规模最大的融资轮次。 华兰疫苗发布公告宣布完成董事会换届选举及高管聘任。现年37岁的安文珏女士正式当选为公司第三届董事会董事长，并继续担任总经理，同时成为公司新任法定代表人。这意味着华兰生物创始人安康先生正式卸任华兰疫苗法定代表人职务，公司管理权平稳交接至“二代”手中。 香港联交所权益披露文件显示，4月15日，高瓴资本Hillhouse旗下二级投资平台HHLR以每股均价8.97港元增持基石药业-B2620万股普通股股份，涉资约2.35亿港元。增持后，HHLR最新持股数目增至8866.45万股。大摩(Morgan Stanley)亦于4月15日以每股均价9.4755港元增持基石药业约795.92万股，总金额约为7541.72万港元。增持后最新持股数目约为7781.96万股，持股比例为5.27%。 Flagship Pioneering宣布正式推出生物技术公司Serif Biomedicines，致力于开发“修饰DNA（Modified DNA）”这一创新药物类别。该公司提出，修饰DNA有望融合mRNA疗法与基因治疗的优势，同时降低两者的局限性，实现可编程、可规模化生产、作用持久且可重复给药的治疗模式。Flagship Pioneering已承诺初始投入5000万美元。 产业动态 翰宇药业与Torrent Pharma INC（就醋酸兰瑞肽缓释注射液（预充式）签署了独家开发、生产及商业化协议。根据协议，翰宇药业将负责醋酸兰瑞肽缓释注射液（预充式）的技术开发与生产供应，Torrent则获得该产品在美国市场的独家商业化权利。醋酸兰瑞肽是一种用于治疗肢端肥大症及某些神经内分泌肿瘤的长效生长抑素类似物。 美国食品药品监督管理局批准了默沙东公司开发的新型双药、每日一次的口服HIV-1感染治疗方案doravirine/islatravir。该药物适用于在接受抗逆转录病毒治疗后病毒载量已得到抑制的成年患者。 罗氏旗下Genentech公司宣布，美国FDA已接受CD20单抗Gazyva（obinutuzumab）用于治疗系统性红斑狼疮（SLE）的补充生物制剂许可证申请，预计12月前做出决定。Gazyva已在美国和欧盟获批用于成人狼疮肾炎，还在100个国家获批用于治疗多种血液系统恶性肿瘤，若此次获批，有望成为SLE新标准治疗。 联系美通社 +86-10-5953 9500 info@prnasia.com